Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 199

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases

Open access
Raeber, Miro E., Sahin, Dilara, Karakus, Ufuk, Boyman, Onur · 2023 · eBioMedicine

Abstract

Abstract Background The cytokine interleukin-2 (IL-2) can stimulate both effector immune cells and regulatory T (Treg) cells. The ability of selectively engaging either of these effects has spurred interest in using IL-2 for immunotherapy of cancer and autoimmune diseases. Thus, numerous IL-2-based biologic agents with improved bias or delivery toward effector immune cells or Treg cells have been developed. These improved IL-2-based compounds recently entered clinical trials. Objective This study systematically reviews clinical results of improved IL-2-based compounds for the treatment of cancer or autoimmune diseases. Methods We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), searched the ClinicalTrials.gov database for registered IL-2 trials using improved IL-2-based agents and different databases for available results of these studies. Results We identified 547 registered clinical trials, of which we extracted 36 studies on improved IL-2-based compounds. Moreover, we assessed another 9 agents reported in two recent literature reviews and based on our knowledge, totaling in 45 improved IL-2-based compounds. A secondary search for registered clinical trials of each of these improved 45 compounds resulted in 139 clinical trials included in this systematic review, with 29 trials reporting clinical results. Conclusions As of yet, none of the improved IL-2-based compounds gained regulatory approval for the treatment of cancer or autoimmune diseases. Three compounds treating cancer have entered phase 3 trials with two studies still ongoing. NKTR-214 is the only compound that has completed phase 3 studies. The PIVOT IO-001 study testing the combination of NKTR-214 plus Pembrolizumab compared to Pembrolizumab monotherapy in metastatic melanoma missed its primary endpoint of superior objective response rate and progression-free survival. The PIVOT-09 study, combining NKTR-214 with Nivolumab compared to Sunitinib or Cabozantinib in advanced renal cell carcinoma, missed its primary endpoint of improved objective response rate. Trials in autoimmune diseases are currently in early stages, thus not allowing conclusions on efficacy. Results of ongoing trials will provide insight into which improved IL-2-based compounds will be beneficial for cancer and autoimmune diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ebiom.2023.104539

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Metadata

Authors
Raeber, M. E., Sahin, D., Karakus, U., & Boyman, O.
Venue
eBioMedicine
Publisher
Elsevier BV
Published
2023-04
Volume
90
Pages
104539
ISSN
2352-3964 (ISSN-L)
OpenAlex
W4362472477
Cited by
199
References
6
FWCI
9.57
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases. https://app.cochat.ai/papers/10.1016/j.ebiom.2023.104539
The paper
Raeber, M. E., Sahin, D., Karakus, U., & Boyman, O. (2023). A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases. eBioMedicine. https://doi.org/10.1016/j.ebiom.2023.104539

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.